P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 10, 1999, Pages 1453-1458

  Duan, James J W ^a   Chen, Lihua ^a   Xue, Chu Biao ^a   Wasserman, Zelda R ^a   Hardman, Karl D ^a   Covington, Maryanne B ^a   Copeland, Robert R ^a   Arner, Elizabeth C ^a   Decicco, Carl P ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; GELATINASE B; MACROCYCLIC COMPOUND; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; STROMELYSIN; AMINE; METALLOPROTEINASE; PROTEINASE INHIBITOR;

AMINATION; ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; ENZYMOLOGY; EXTRACELLULAR MATRIX;

AMINES; COMPUTER SIMULATION; EXTRACELLULAR MATRIX; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; PROTEASE INHIBITORS;

EID: 0033577572     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00215-2     Document Type: Article

References (21)

1. Department of Inflammatory Diseases Research, P.O. Box 80400.
2. Stoker, W.; Grams, F.; Bauman U.; Reinemer, P.; Gomis-Ruth, F.-X.; McKay, D. B.; Bode, W. Protein Sci. 1995, 4, 823.
3. Nagase, H. In Zinc Metalloproteases in Health and Disease; Hooper, N. M., Ed.; Taylor and Francis Ltd.: London, 1996; pp 152-204.
4. Initial presentation on these inhibitors: Chen, L.; Duan, J. J.-W.; Xue, C.-B.; Covington, M. B.; Welch, P. K.; Copeland, R.; Arner, E. C.; Decicco, C. P. Abstracts of Papers, 214th National Meeting of the American Chemical Society, Las Vegas, NV, American Chemical Society: Washington DC, 1997, MEDI 98.
5. (a) Beckett, R. P.; Whittaker, M. Exp. Opin. Ther. Patents 1998, 8, 259.
6. (b) Zask, A.; Levin, J. I.; Killar, L. M.; Skotnicki, J. S. Curr. Pharm. Design 1996, 2, 624.
7. (c) Hagmann, W. K.; Lark, M. W.; Becker, J. W. Ann. Rep. Med. Chem. 1996, 31, 231.
8. (a) Xue, C.-B.; He, X.; Roderick, J.; Degrado, W. F.; Cherney, R.; Hardman, K.; Nelson, D. J.; Copeland, R. A.; Jaffee, B. D.; Decicco, C. P. J. Med. Chem. 1998, 41, 1745.
9. (b) Cherney, R. J.; Wang, L.; Meyer, D. T.; Xue, C.-B.; Wasserman, Z. R.; Hardman, K. D.; Welch, P. K.; Covington, M. B.; Copeland, R. A.; Arner, E. C.; Degrado, W. F.; Decicco, C. P. J. Med. Chem. 1998, 41, 1749.
10. For an example of enhanced resistance to enzymatic degradation through macrocyclization, see: Sham, H. L.; Bolis, G.; Stein, H. H.; Fesik, S. W.; Marcotte, P. A.; Plattner, J. J.; Rempel, C. A.; Greer, J. J. Med. Chem. 1988, 31, 284.
11. Steinman, D. H.; Curtin, M. L.; Garland, R. B.; Davidsen, S. K.; Heyman, H. R.; Holms, J. H.; Albert, D. H.; Magoc, T. J.; Nagy, I. B.; Marcotte, P. A.; Li, J.; Morgan, D. W.; Hutchins, C.; Summers, J. B. Bioorg. Med. Chem. Lett. 1998, 8, 2087.
12. For related examples of macrocyclic inhibitors of Zn metalloproteinases, see: (a) Ksander, G. M.; de Jesus, R.; Yuan, A.; Ghai, R. D.; McMartin, C.; Bohacek, R. J. Med. Chem. 1997, 40, 506.
13. (b) Ksander, G. M.; de Jesus, R.; Yuan, A.; Ghai, R. D.; Trapani, A.; McMartin, C.; Bohacek, R. J. Med. Chem, 1997, 40, 495.
14. Luty, B. A.; Wasserman, Z. R.; Stouten, P. F. W.; Hodge, C. N.; Zacharias, M.; McCammon, J. A. J. Comput. Chem. 1995, 16, 454.
15. (a) Frater, G. Helv. Chem. Acta 1979, 62, 2827.
16. (b) Frater, G.; Muller, U.; Gunther, W. Tetrahedron 1984, 40, 1269.
17. 2O. For a related reference see: Abood, N. A. Synth. Commun. 1993, 25, 811.
18. 2. For a related reference see: Saito, S.; Ishikawa, T.; Kuroda, A.; Koga, K.; Moriwake, T. Tetrahedron 1992, 48, 4067.
19. 13C NMR, LRMS and HRMS. In addition, analytical samples of compounds 11, 12 and 2b gave satisfactory C and H combustion analysis.
20. Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. J. Org. Chem. 1981, 46, 3936.
21. Seed, M. P. Exp. Opin. Invest. Drugs 1996, 5, 1617.